Core Insights - Arteris, Inc. reported record Annual Contract Value (ACV) plus royalties of $69.1 million for Q2 2025, marking a 15% year-over-year increase, and a Remaining Performance Obligation (RPO) of $99.3 million, up 28% year-over-year [2][7] - The company anticipates Q3 2025 ACV plus royalties in the range of $69.5 million to $72.5 million and full-year 2025 revenue guidance of $66.0 million to $70.0 million [6] Financial Highlights - Revenue for Q2 2025 was $16.5 million, reflecting a 13% increase year-over-year [7] - Non-GAAP operating loss for Q2 2025 was $3.5 million, unchanged from Q2 2024 [7] - Net loss for Q2 2025 was $9.1 million, or $0.22 per share, compared to a net loss of $8.3 million in Q2 2024 [7][18] Business Highlights - The company secured a licensing agreement with AMD for its FlexGen smart network-on-chip IP, aimed at enhancing data transport for AI chiplets [7] - Arteris announced a significant customer win with Whalechip, which is licensing FlexNoC 5 for high-performance AI computing [7] - The company expanded its multi-die solution to support Universal Chiplet Interconnect Express (UCIe) and collaborated with major partners for chiplet interface support [7] Guidance - Estimated Q3 2025 revenue is projected between $16.8 million and $17.2 million, with a full-year revenue forecast of $66.0 million to $70.0 million [6] - Non-GAAP operating loss for Q3 2025 is expected to be between $3.0 million and $4.0 million, with a full-year estimate of $10.5 million to $15.5 million [6] Cash Flow and Liquidity - Free cash flow for Q2 2025 was negative at $2.8 million, compared to positive free cash flow of $0.3 million in Q2 2024 [34] - The company ended Q2 2025 with cash and cash equivalents of $16.1 million, an increase from $13.7 million at the end of Q4 2024 [20]